Sensei Biotherapeutics SNSE

$ 0.44 2.09%

Quarterly report 2024-Q3
added 11-14-2024

Sensei Biotherapeutics Balance Sheet 2011-2024 | SNSE

Annual Balance Sheet Sensei Biotherapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-10.7 M	-15 M	-5.48 M	-15.5 M	15.8 M	4.09 M	-	-	-	-	-	-	-
Long Term Debt	768 K	1.58 M	1.67 M	567 K	-	4.05 M	-	-	-	-	-	-	-
Long Term Debt Current	1.57 M	1.25 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	73 M	48.2 M	52.7 M	-	-	-	-	-	-	-
Total Current Liabilities	5.64 M	9.07 M	4.89 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	9.48 M	15 M	6.71 M	77.9 M	69.9 M	55.3 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-232 M	-198 M	-149 M	-112 M	-92.3 M	-75.6 M	-	-	-	-	-	-	-
Total Assets	74.4 M	118 M	153 M	21.4 M	1.22 M	1.85 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	13 M	17.8 M	7.16 M	-	-	-	-	-	-	-	-	-	-
Book Value	64.9 M	103 M	147 M	-56.4 M	-68.7 M	-53.5 M	-	-	-	-	-	-	-
Total Shareholders Equity	64.9 M	103 M	147 M	-56.4 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Sensei Biotherapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	206 K	377 K	571 K	768 K	962 K	1.16 M	1.35 M	1.58 M	1.68 M	1.72 M	1.85 M	1.67 M	-	567 K	567 K	567 K	567 K	567 K	567 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	7.48 M	7.61 M	8.22 M	9.48 M	10.7 M	10.4 M	13.1 M	15 M	14.8 M	12.1 M	14.7 M	6.71 M	6.04 M	4.6 M	3.22 M	5.54 M	5.54 M	5.54 M	5.54 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-254 M	-247 M	-240 M	-232 M	-224 M	-217 M	-208 M	-198 M	-186 M	-172 M	-162 M	-149 M	-140 M	-130 M	-120 M	-112 M	-112 M	-112 M	-112 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	53.3 M	59.8 M	66.7 M	74.4 M	81.7 M	89.6 M	108 M	118 M	129 M	138 M	150 M	153 M	161 M	168 M	174 M	21.4 M	21.4 M	21.4 M	21.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	19.1 M	11.9 M	11 M	13 M	11.3 M	10.2 M	8.11 M	17.8 M	11.4 M	9.9 M	8.72 M	7.16 M	9.53 M	15.6 M	169 M	16.6 M	16.6 M	16.6 M	16.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	45.8 M	52.2 M	58.5 M	64.9 M	71 M	79.2 M	94.8 M	103 M	114 M	126 M	135 M	147 M	155 M	163 M	171 M	15.9 M	15.9 M	15.9 M	15.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	45.8 M	52.2 M	58.5 M	64.9 M	71 M	79.2 M	94.8 M	103 M	114 M	126 M	135 M	147 M	155 M	163 M	171 M	-56.4 M	-56.4 M	-56.4 M	-56.4 M	-68.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency